TITLE
Risto Kontio & Hanna Välimaa: Prevention of MRONJ – Consider risk factors: what the current literature says
TALK INFO
This educational session focused on Medication-Related Osteonecrosis of the Jaw (MRONJ), with emphasis on prevention and risk factor assessment based on the most current clinical literature. The lecture was part of a broader series addressing MRONJ — a serious complication associated with antiresorptive and antiangiogenic medications used in oncology and osteoporosis care. The session reviewed why MRONJ occurs, how to identify patients at risk, and evidence-based preventive strategies, especially in patients undergoing dental, oral surgical, or maxillofacial procedures.
THIS EVENT IS ACCREDITED
CLINICAL PATHWAY
Pathology, Medical Assessment and Management
SPEAKER
DATE
15/01/24
LEARNING OBJECTIVES
By the end of this session, attendees were expected to be able to:
Describe the current understanding of MRONJ pathophysiology and epidemiology — including why the jaw is particularly susceptible and how medications such as bisphosphonates and denosumab contribute to risk.
Identify and interpret documented risk factors related to MRONJ development (e.g., drug type, dose and duration, systemic co-morbidities like diabetes or corticosteroid use, and local factors such as dental extractions or periodontal disease).
Apply evidence-based prevention strategies — including assessment before initiating antiresorptive therapy, optimizing oral health, careful dental treatment planning, and how to integrate findings from recent literature into clinical decision-making.
Evaluate the role of multidisciplinary care in minimizing MRONJ risk — highlighting the importance of collaboration among surgeons, dentists, microbiologists, and other healthcare professionals.
ABOUT THE SPEAKER
Dr. Risto Kontio
Oral & Maxillofacial (OMF) Surgeon by training
Co-editor of Medication-Related Osteonecrosis of the Jaw (MRONJ) – A Guide to Research
Affiliated with the Department of Maxillofacial Surgery at Helsinki University
Recognized for research and clinical expertise in MRONJ pathogenesis, management, and prevention.Dr. Hanna Välimaa
Specialist in Clinical Microbiology
Also based at Helsinki University Hospital (Department of Maxillofacial Surgery)
Contributed to the discussion on microbiological and systemic aspects of MRONJ and its prevention.
CE ACCREDITATION
surgeOn is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry. surgeOn designates this activity for 1 credit hour of continuing education credits.
This event may also be accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 1 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. If you are a learner based in the U.S. or Canada EACCME credits are recognized by the American Medical Association (AMA) and the Royal College of Physicians and Surgeons of Canada.
DECLARATION
In accordance with criterion 13 of document UEMS 2023.07.rev “EACCME® Criteria for the Accreditation of Live Educational Events (LEEs)” and the Standard v. Commercial or Promotional Conflict of Interest, published by the American Dental Association Continuing Education Recognition Program (ADA CERP), all surgeON presenters sign a Conflict of Interest form to document all perceived or actual conflicts of interest for the last 3 years, whether due to a financial or other relationship. This document can be viewed at the beginning of the event or on request by emailing info@surgeon-events.org No fee, honorarium or arrangement for re-imbursement of expenses in relation to the this event has been provided to the speaker.
